Clinical Trials Browser

Neuroendocrine Tumors × SNX-5422 × NET × Clear all

NCT02063958 2018-07-30

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

Phase 1 Completed

Neoplasms, Neuroendocrine Tumors